Shah Heer, Nagi Jasleen, Khare Shivank, Hassan Hana, Siu Anthony
General Surgery, Southend University Hospital, Essex, GBR.
Internal Medicine, Imperial College London School of Public Health, London, GBR.
Cureus. 2023 Mar 30;15(3):e36899. doi: 10.7759/cureus.36899. eCollection 2023 Mar.
The overarching aim of pharmacovigilance is to ensure the safe and effective usage of medication across the population and optimise medicines through holistic considerations. However, within the heterogeneous elderly population, several unique factors are at play, limiting the ability of clinicians to fulfil this aim. A matured physiology influencing the response and effects of drugs, increased polypharmacy enabling drug-drug interactions, and greater consumption of concurrent herbal medicines predispose patients to harmful drug events. This increasingly multimorbid subpopulation requires complex pharmaceutical regimens encouraging inappropriate prescribing and medicine non-adherence leading to suboptimal therapy. Furthermore, restrictive practices in clinical trials commonly exclude elderly patients creating disparities from expected findings within a real-world setting. These issues create an environment where elderly patients are at a heightened risk of adverse drug events and clinicians are forced to make significant decisions from limited information. With projections showing that this demographic will continue growing in size, the true burden of these limiting factors is yet to be realised.
药物警戒的总体目标是确保全体人群安全有效地使用药物,并通过全面考量优化药物。然而,在异质性的老年人群体中,有几个独特因素在起作用,限制了临床医生实现这一目标的能力。成熟的生理机能影响药物的反应和效果,多重用药增加导致药物相互作用,同时草药的大量使用使患者易发生有害药物事件。这个日益多病的亚群体需要复杂的药物治疗方案,这会导致不适当的处方和药物治疗依从性差,从而导致治疗效果不佳。此外,临床试验中的限制性做法通常会排除老年患者,导致实际情况与预期结果存在差异。这些问题营造了一种环境,使老年患者发生药物不良事件的风险增加,临床医生不得不根据有限的信息做出重大决策。预计这一人群规模将持续增长,这些限制因素的真正负担尚未显现。